The March 2026 NHS England Board papers show that data is becoming one of the main instruments through which the NHS will manage delegated accountability. 

This is most visible in the Board papers on new Directions issued to NHS England by the Secretary of State for Health and Social Care. These Directions require NHS England to collect and analyse information from relevant health and care bodies about services commissioned by integrated care boards, where direct commissioning functions have been delegated to ICBs.  

The immediate scope includes new data collections for community pharmacy clinical services and dental and orthodontic activity. But the wider signal is more significant than these two datasets alone. NHS England is pairing local responsibility with stronger national information flows, benchmarking, pathway analysis and assurance.  

The core signal is clear: as more responsibility is delegated locally, the NHS accountability model is becoming more data-led, more transparent and more focused on whether commissioned services are safe, effective, value-led and reducing inequalities. 

System Incentive Lens

The system pressure behind this direction is the need to give ICBs greater responsibility for local population health while preserving national assurance over safety, effectiveness, value for money and health inequalities. The financial and operational constraint is that the NHS must improve access, productivity and quality while local systems remain under significant pressure.  

The behavioural incentive is to ensure that delegated commissioning does not become fragmented or opaque. Better data is intended to support benchmarking, identify variation, target inefficiencies and improve understanding of patient pathways. The operational trade-off is that stronger data collection can improve assurance, but only if data quality, information governance and frontline reporting burden are managed carefully. 

Delegation is being paired with retained accountability

The Delegation of NHS England Direct Commissioning Functions Evaluation and Monitoring of Services Directions 2026 are important because they clarify the relationship between local commissioning responsibility and national accountability. 

The Board paper states that NHS England is responsible for making sure that health services commissioned by ICBs are safe, effective, delivering value for money and reducing health inequalities. It also states that NHS England retains overall accountability for the discharge of delegated functions and requires the necessary assurances from ICBs that functions are being discharged safely and effectively.  

This is the central governance signal. Delegation does not mean the centre steps away. Instead, it means local systems carry more responsibility while NHS England strengthens the information infrastructure needed to monitor, evaluate and assure delivery. 

The Directions require NHS England to collect and analyse information relating to delegated functions so it can monitor national and local service performance, understand whether services are achieving desired aims and patient benefits, understand the impact on the wider NHS, assess patient pathways and outcomes, inform priority setting, support population health management, enable benchmarking and target inefficiencies.  

For ICBs, this changes the practical meaning of delegated responsibility. It is not only about holding functions locally. It is about being able to evidence how those functions are being discharged, what outcomes they support, how they affect wider system flow and where improvement is required. 

For providers and commissioned services, the message is equally clear: activity, quality, safety, value and outcome data will matter more as part of local and national assurance. 

Community pharmacy and dental data are the first signals

The Directions operate as framework Directions. This means they establish a broad purpose for data collection and analysis, with separate requirements specifications to be put in place over time for different data collections. The initial two requirements specifications relate to community pharmacy clinical services and dental and orthodontic activity.  

The Community Pharmacy Clinical Services Dataset relates to services such as Pharmacy First and the Blood Pressure Check Service. NHS England will collect and analyse data about the care given when patients access community pharmacy services, including the nature of consultations, reasons for visits, medicines prescribed and referrals to other NHS services such as the patient’s GP, NHS 111 or accident and emergency.  

The Dental and Orthodontic Activity Dataset will collect and analyse data about the care given to patients when they access NHS dental and orthodontic services, including the type of dental treatment received.  

These may appear to be narrow service-specific datasets. They are not. They point to a broader operating model in which services outside acute hospitals are brought more clearly into national visibility. 

That matters because the NHS’s future direction depends on neighbourhood health, prevention, community-based care, primary care access, pharmacy integration and better management of demand before it reaches hospital. The Strategy Committee’s March update confirms that payment reform, neighbourhood health services, workforce planning, urgent and emergency care redesign and productivity planning are all being developed as part of the wider strategic pipeline.  

The data signal is therefore strategic. If more care is to be delivered outside hospital, the system needs better data on what is happening outside hospital. 

Data is becoming the infrastructure of performance oversight

The March Board pack shows that NHS England is already operating in a more data-led performance environment. 

The Integrated Performance Report provides detailed visibility across access, effectiveness, experience, patient safety, workforce and inequalities. It shows provider and system variation across elective waiting lists, Referral to Treatment performance, cancer standards, diagnostic waits, community waits, urgent and emergency care, mortality indicators, CQC safe ratings, sickness absence, staff engagement and raising-concerns scores.  

This is not simply performance reporting. It is becoming the infrastructure for intervention. Where variation is visible, systems can be tiered, providers can be supported, recovery actions can be targeted and national oversight can focus on areas where patients face the greatest delay or risk. 

The February Board minutes show the same direction of travel. The Board supported greater transparency and increased use of the Federated Data Platform for reporting. It also supported extending transparency across non-acute services and patient experience datasets, linking information to patient choice tools and considering publication of clinical outcome metrics by specialty.  

This is highly relevant to the delegation agenda. If ICBs are responsible for local population health and delegated services, then the centre needs data that can show how services are performing, where inequalities are emerging, how pathways are functioning and where variation is not justified. 

For provider and system leaders, the implication is that data quality is becoming a leadership issue. Incomplete, inconsistent or delayed data will not only affect reporting. It may affect planning, assurance, performance oversight, patient choice, commissioning decisions and public transparency. 

Research data shows the importance of trust and safeguards

The March Board papers also include the GPES Data for Consented Research Directions 2026. These Directions enable NHS England to establish a service through which certain information already collected from General Practice health records can be shared with specific approved research studies.  

The safeguards are central. The data can only be accessed for participants where explicit consent has been provided, or where it is lawful under the Mental Capacity Act 2005 for research to be carried out in relation to a patient who lacks capacity. The paper also states that approved research studies must meet access criteria, use a Secure Data Environment for onward availability to third-party researchers, and satisfy NHS England that consent or lawful authority requirements are met.  

Three studies are identified as being in the process of seeking approval to become approved research studies and access data through the new service: UK Biobank, Our Future Health and Genomics England Limited. NHS England states that audits of consenting processes were undertaken in 2025 and considered satisfactory, and that a Consent Review Assurance Group reviewed the arrangements.  

This matters because the NHS data agenda depends on public trust. The value of data for research, population health, service planning and innovation is substantial. But that value can only be realised if consent, lawful authority, information governance, transparency and patient protection are treated as foundational. 

The paper states that NHS England is directed not to publish any data obtained by virtue of these Directions. It also states that no new data collection is required from GP practices for this purpose, because the data is already held by NHS England for COVID-19 purposes.  

The system signal is balanced: data can support research and improve understanding of health and care, but only within strong governance boundaries. 

Accountability will depend on digital and workforce capacity

The new accountability model depends on data, but data depends on people, systems and leadership. 

The Data, Digital and Technology Committee’s March update is therefore important. The Committee supports the direction of digital change, but it identifies significant constraints: unclear prioritisation in cyber work, slow progress on a national business continuity exercise following a severe cyber-attack, limited business ownership for accelerated digital programmes, no completed technical or operational deliverability assessment, and unresolved programme coherence.  

Most significantly, the Committee states that the Voluntary Redundancy Programme represents a material and currently unmitigated risk because scarce specialist capacity is being drawn away from critical cyber and resilience work. It also states that the absence of permanent executive leadership and the ongoing impact of the programme are material constraints that, if not addressed, will limit delivery.  

This is directly relevant to data and delegation. A more data-led accountability model cannot be delivered through policy direction alone. It requires specialist digital, data, information governance, analytical, cyber and operational capability. It also requires local teams who can collect, validate, interpret and use data without excessive reporting burden. 

The People Committee also notes the importance of maintaining oversight of workforce capability and organisational capacity as the Voluntary Redundancy Programme progresses, with particular attention to specialist capability and key organisational knowledge.  

For NHS leaders, the practical implication is that data accountability must be matched with delivery capacity. Otherwise, the system risks creating stronger expectations without the capability needed to meet them. 

The new model links data,valueand patient outcomes

The Delegation Directions explicitly connect data collection to safety, effectiveness, value for money and health inequalities. That makes them part of the wider productivity and quality agenda.  

The Strategy Committee’s March update reinforces this connection. The Committee reviewed a Productivity Plan aimed at achieving 2% annual productivity growth, with reducing unwarranted variation identified as the core strategy for baseline productivity gains. It also reviewed payment system reform centred on linking payment to patient experience, activity, true service costs and neighbourhood health services.  

Data is the common thread. Reducing variation requires data. Linking payment to activity and experience requires data. Understanding true service cost requires data. Supporting neighbourhood health requires data. Monitoring delegated services requires data. Improving patient pathways and outcomes requires data. 

The Month 10 finance paper shows why this is operationally urgent. Although the NHS was broadly in balance nationally, systems were overspending by £428 million year to date and 14 systems were formally forecasting year-end overspends. In that context, data that supports benchmarking, inefficiency targeting and pathway improvement becomes central to financial grip as well as quality improvement.  

For patients, the intended benefit is clearer: services should be better understood, better monitored and more consistently improved. For healthcare workers, the benefit should be better pathway visibility and decision support. But the risk is that data requirements become another administrative layer unless they are designed around operational usefulness. 

The real test will be whether data improves care, not only oversight. 

What this means now

The March Board papers show that the NHS is moving towards a new accountability model in which delegation and data are inseparable. 

ICBs are being given responsibility for managing local population health needs and delegated services, but NHS England retains overall accountability and is strengthening the data required to assure safety, effectiveness, value for money and inequality reduction. The first data collections under the framework cover community pharmacy clinical services and dental and orthodontic activity, but the broader signal is a system-wide move towards more visible, benchmarked and evidence-led commissioning oversight.  

For patients, the opportunity is better understanding of pathways, outcomes, access and service quality. For healthcare workers, the opportunity is data that supports improvement, reduces duplication and helps services target need more effectively. For provider and ICB leaders, the challenge is to ensure data quality, information governance, workforce capacity and operational ownership are strong enough to support the model. 

The implication is direct. Clinical capacity, staffing support and medico-legal assurance will increasingly sit within a more transparent delivery environment. Activity will need to be evidenced. Workforce models will need to show value and safety. Clinical risk will need to be understood through pathway data, documentation and outcome visibility. Support that cannot demonstrate contribution to access, quality, productivity or patient safety will become harder to justify. 

The central system implication is this: delegation will only strengthen NHS delivery if local responsibility is matched by reliable data, strong governance and the capability to act on what the data shows. 

The NHS does not need more data for its own sake. It needs data that improves decisions, reduces variation, strengthens accountability and helps patients receive safer, more timely and more equitable care. 

References

• NHS England, Summary of Delegation of NHS England Direct Commissioning Functions Evaluation and Monitoring of Services Directions 2026, March 2026. 
• NHS England, Summary of GPES Data for Consented Research Directions 2026, March 2026. 
• NHS England, Integrated Performance Report, March 2026. 
• NHS England, Board Committee updates – Data, Digital and Technology Committee, March 2026. 
• NHS England, Board Committee updates – NHS England Strategy Committee, March 2026. 
• NHS England, Board Committee updates – NHS England People Committee, March 2026. 
• NHS England, Month 10 financial position 2025/26, March 2026. 
• NHS England, Minutes of a public meeting of the NHS England Board held on Thursday 5 February 2026, published March 2026.